Evidence Table 81. KQ2—Continuous data—Platelet aggregability

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gardner 200723  Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:1.3  Median:  SD:  6.00%  P: | Mean:  Median:  SD:  P: | No difference in groups (p=0.2) | low |
|  | Placebo | 26 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:-2.7  Median:  SD:  10.00%  P: |
| Gardner 200723  Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean: -1.3  Median:  SD:  12.00%  P: | Mean:  Median:  SD:  P: | No difference in groups (p=0.15) | low |
|  | Placebo | 26 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean4.2  Median:  SD:  12.60%  P: |

| Evidence Table 81. KQ2—Continuous data—Platelet aggregability (continued) | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Gardner 200723  Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean: -4.1  Median:  SD:  14.90%  P: | Mean:  Median:  SD:  P: | No difference in groups (p=0.7) | low |
|  | Placebo | 26 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean -6  Median:  SD:  19.60%  P: |
| Gardner 200723  Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean: -1.5  Median:  SD:  18.70%  P: | Mean:  Median:  SD:  P: | No difference in groups (p=0.3) | low-medium |
|  | Placebo | 26 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean -6.3  Median:  SD:  18.70%  P: |
| Steiner 199562  Parallel | At high risk for CHD | ASA | 325 | Vitamin E | 25 | platelet adhesion to collagen III | Mean: 2.7  Median  SD: 0.4  SE:  Lower:  Upper: | Mean:  % mean: 40  Median:  SD:  P:  <0.0001 | Mean:  Median:  SD:  P: | please ensure about the unit. the difference is reported for change from baseline in the vit E group only. | medium |
|  | Placebo | 48 | Mean:4.4  Median  SD: 0.8  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Kim 201035  crossover | Low and/or Moderate | Ticlopidine | 250- single dose | ginkgo biloba | 24 | 5μl of 10 μM ADP | Mean: 63  Median  SD: 18.9  SE:  Lower:  Upper: | Mean:-3.6  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | Mean ratio of ginkgo/No treatment: 1.02 | medium  medium |
|  | No treatment | 24 | Mean:64.8  Median  SD: 19.7  SE:  Lower:  Upper: | Mean:-3.5  Median:  SD:  P: |
| Kim 201035  crossover | Low and/or Moderate | Ticlopidine | 250- single dose | ginkgo biloba | 24 | 1 μL of 2 μg/mL collagen | Mean: 80.4  Median  SD: 11.2  SE:  Lower:  Upper: | Mean:3.5  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | Mean ratio of ginkgo/No treatment: 1.03 | medium |
|  | No treatment | 24 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Jiang 200433 | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Ginseng | 12 | Arachidonic acid  10 ml of 50 mM concentration | Mean: 7.1  Median  SD: 1.4  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:1  Median:  SD:  P: | 95% CI of mean for individual group data: Ginseng group: 6-7.8; St. Johns Wort: 6.5-8.2; No treatment group: 5.6-9.1 | medium |
|  | St. John’s | 12 | Mean: 7.5  Median  SD: 1.1  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: |
|  | No treatment | 12 | Mean:7.7  Median  SD: 2.2  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Jiang 200532 | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Gingko Biloba | 12 | Arachidonic acid | Mean: 8.4  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:1.14  Median:  SD:  P: | 95% CI of mean for individual group data: ginkgo group: 7.60-9.20; Ginger group: 7.50-8.70; No treatment group: 6.50-8.40 | medium |
|  | Ginger | 12 | Mean: 8.1  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: |
|  | No treatment | 12 | Mean:7.5  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Aruna 20072  crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 10μM ADP | Mean: 77  Median  SD: 20  SE:7  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | 95% CI of mean for individual group data: ginkgo group: 39.00-73.00; No treatment group: 36.00-82.00 | medium |
|  | No treatment | 10 | Mean:59  Median  SD: 13  SE:10  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Aruna 20072  crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 10μM ADP | Mean: 56  Median  SD: 19  SE:7  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | 95% CI of mean for individual group data: ginkgo group: 61.00-92.00; No treatment group: 41.00-79.00. | medium |
|  | No treatment | 10 | Mean:60  Median  SD: 23  SE:8  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Aruna 20072  crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 5μM ADP | Mean: 57  Median  SD: 22  SE:8  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | 95% CI of mean for individual group data: ginkgo group: 39.00-75.00 p-value <0.05; No treatment group: 23.00-72.00, p-value <0.05. | medium |
|  | No treatment | 10 | Mean:47  Median  SD:32  SE:11  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Aruna 20072  crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 5μM ADP | Mean: 49  Median  SD: 21  SE:8  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | 95% CI of mean for individual group data: ginkgo group: 31.00-67.00, p-value <0.05; No treatment group: 30.00-73.00, p-value < 0.05. | medium |
|  | No treatment | 10 | Mean:52  Median  SD: 26  SE:9  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Mohammed Abdul 200849  Crossover | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Garlic | 12 | assessed on blood samples (within 3 h of blood collection) collected 24 h prior to warfarin administration ( 24 h) in each treatment period using a whole blood aggregometer (Chrono-par; Chrono-log Corp., Havertown, Pennsylvania, USA; Edward Keller Australia Pty Ltd, Hallam, VIC, Australia). Method described further but not extracted | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | "…2 weeks of pretreatment with garlic…had no effect on platelet aggregation." | medium |
|  | No treatment | 12 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| McKenney 200645  Crossover | Low and/or Moderate | simvastatin | 80 | Omega-3 | 24 | ADP | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean: -3.4  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | No treatment | 23 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean -4.5  Median:  SD:  P: |
| McKenney 200645  Crossover | Low and/or Moderate | simvastatin | 80 | Omega-3 | 24 | Collagen | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:-5.1  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | No treatment | 23 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean -6  Median:  SD:  P: |
| Abdul 20101 | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Echinacea | 11 | 10μM ADP | Mean: 7.5  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:0.84  Median:  SD:  P: | Post treatment mean 95% CI: Echinacea group 4.1-10.8; No treatment group 5.5-10. | medium |
|  | No treatment | 11 | Mean:7.8  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Abdul 20101 | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Echinacea | 11 | Arachidonic acid  0.5mM | Mean: 12.1  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:1.06  Median:  SD:  P: | Post treatment mean 95% CI: Echinacea group 9.3-15; No treatment group 9.6-12.5. | medium |
|  | No treatment | 11 | Mean:11  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Abdul 20101 | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Echinacea | 11 | Collagen-induced  2μg/ml | Mean:15.8  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: | Mean:1  Median:  SD:  P: | Post treatment mean 95% CI: Echinacea group 12.2-19.5; No treatment group 11.5-14.6. | medium |
|  | No treatment | 11 | Mean:13  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |  |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Collagen-induced  at 7 days after treatment | Mean: 81  Median  SD: 8.6  SE:  Lower:  Upper: | Mean:  % mean: -5.6  Median:  SD:  P: | Mean:  Median:  SD:  P: | ratio of means presented with 90% CI | medium |
|  | Placebo | 50 | Mean:81  Median  SD: 12.7  SE:  Lower:  Upper: | Mean:  % mean: -3.5  Median:  SD:  P: |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Adenosine diphosphate-induced  at day 7 after treatment | Mean: 44.8  Median  SD: 18.1  SE:  Lower:  Upper: | Mean:  % mean: -26.9  Median:  SD:  P: | Mean:0.95  Median:  SD:  P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:47.2  Median  SD: 15.1  SE:  Lower:  Upper: | Mean:  % mean: -25.4  Median:  SD:  P: |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Arachidonate-induced  at day 7 after treatment | Mean: 2.2  Median  SD: 2.1  SE:  Lower:  Upper: | Mean:  % mean: -76  Median:  SD:  P: | Mean:0.65  Median:  SD:  P: | ratio of means reported with 90% CI; 100 put in as top of 90% CI but actually infinity | low-medium |
|  | Placebo | 50 | Mean:3.4  Median  SD: 10.4  SE:  Lower:  Upper: | Mean:  % mean:-75.1  Median:  SD:  P: |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Ristocetin-induced  at 7 days, after treatment | Mean: 90  Median  SD: 10.5  SE:  Lower:  Upper: | Mean:  % mean: -6.5  Median:  SD:  P: | Mean:0.98  Median:  SD:  P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:92.2  Median  SD: 12.3  SE:  Lower:  Upper: | Mean:  % mean:-4.1  Median:  SD:  P: |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Epinephrine-induced  at 7 days after treatment | Mean: 13.7  Median  SD: 7.7  SE:  Lower:  Upper: | Mean:-7.1  % mean:  Median:  SD:  P: | Mean:0.99  Median:  SD:  P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:13.8  Median  SD: 6.8  SE:  Lower:  Upper: | Mean:  % mean:-6.5  Median:  SD:  P: |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Platelet-activating factor-induced  at day 7 after treatment | Mean: 4.8  Median  SD: 3.7  SE:  Lower:  Upper: | Mean:  % mean: -22.3  Median:  SD:  P: | Mean:0.69  Median:  SD:  P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:6.9  Median  SD: 11.5  SE:  Lower:  Upper: | Mean:  % mean:-23.2  Median:  SD:  P: |
|  | Placebo | 50 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: |